Pharmacokinetics of a Pediatric Tribendimidine Dose-Finding Study To Treat Hookworm Infection in African Children by Hiroshige, Noemi et al.
Pharmacokinetics of a Pediatric Tribendimidine Dose-Finding
Study To Treat Hookworm Infection in African Children
Noemi Hiroshige,a,b Jean Coulibaly,a,b,c,d Jörg Huwyler,e Peter L. Bonate,f Jennifer Keisera,b
aDepartment of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Basel,
Switzerland
bUniversity of Basel, Basel, Switzerland
cUnité de Formation et de Recherche Biosciences, Université Félix Houphouët–Boigny, Abidjan, Côte d'Ivoire
dCentre Suisse de Recherches Scientiﬁques en Côte d'Ivoire, Abidjan, Côte d'Ivoire
eDepartment of Pharmaceutical Sciences, Division of Pharmaceutical Technology, University of Basel, Basel,
Switzerland
fAstellas, Northbrook, Illinois, USA
ABSTRACT Tribendimidine is a broad-spectrum anthelminthic available in China,
which is currently being pursued for U.S. Food and Drug Administration approval for
soil-transmitted helminth infections. Pharmacokinetic (PK) studies with tribendimi-
dine in children, the main target group for treatment programs, have not been con-
ducted to date. In the framework of a dose-ranging study in hookworm-infected
school-aged children in Côte d’Ivoire, children were treated with either 100, 200, or
400 mg tribendimidine. Dried blood spot samples were collected up to 22 h after
treatment. The active metabolite, deacetylated amidantel (dADT) and its metabolite
acylated dADT (adADT) were quantiﬁed using liquid chromatography tandem mass
spectrometry. PK parameters were calculated using a noncompartmental model, and
univariate logistic regression was applied using maximal blood concentrations (Cmax)
and area under the blood concentration-time curve for 0 to 22 h (AUC0–22) as pre-
dictors of drug efﬁcacy. Dried blood spot samples of 101 children were analyzed. We
observed a less than proportional and proportional exposure in dADT’s median Cmax
and AUC0–22, respectively, following administration of 100 mg (Cmax  853 ng/ml;
AUC0–22  3,019 h · ng/ml) and 400 mg (Cmax  2,275 ng/ml; AUC0–22  12,530 h ·
ng/ml) tribendimidine. There were large, dose-independent variations in the time to
Cmax (Tmax) and ratios of dADT to adADT. We did not detect an inﬂuence of Cmax or
AUC0–22 of dADT or adADT on drug efﬁcacy or adverse events. Since our study pop-
ulation was bearing hookworm infection of mainly low intensity, additional studies
with heavy intensity infections might be required to conﬁrm this observation.
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An estimated 400 to 500 million people are globally infected with hookworms,mainly with the two hookworms Necator americanus and Ancylostoma duodenale.
Hookworms belong to the soil-transmitted helminths and infections are endemic in
tropical and subtropical areas, including Southeast Asia, Papua New Guinea, most of
Africa, and Central and South America (1, 2). Infection with blood-feeding hookworms
is associated with intestinal blood loss leading to iron deﬁciency and anemia. Chronic
infections during childhood and puberty can stunt physical and cognitive development
(2). Preventive chemotherapy with a single dose of albendazole or mebendazole is
applied to control the disease burden (3). However, infections are not fully cured, and
there is a trend of decreasing efﬁcacy of the benzimidazoles, which might be due to
emerging drug resistance, as observed in the veterinary ﬁeld (4, 5). Alternative drugs,
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which could be used in addition to these heavily applied drugs, would decrease the
probability for the emergence of drug resistance by alleviating drug pressure.
Tribendimidine, developed and approved in China in 2004 for the treatment of
soil-transmitted helminth infections, is known for its comparable drug efﬁcacy and
safety to albendazole (6–8). Tribendimidine is a prodrug which degrades quickly to
deacylated amidantel (dADT) and the terephtaldehyde. dADT is further metabolized to
acylated dADT (adADT) probably by arylamine N-acetyltransferases (9). dADT is the
major compound responsible for drug activity against hookworm in vitro and in vivo as
opposed to adADT (10), acting as a selective B-subtype nicotinic acetylcholine receptor
(nAChR) agonist, depolarizing muscular nAChRs of the parasite. This mechanism of
action is different from other nAChR agonistic anthelminthics such as levamisole and
pyrantel (11).
The long clinical experience has proven excellent efﬁcacy and safety of tribendimi-
dine (8), and efforts to register tribendimidine with the U.S. Food and Drug Adminis-
tration (FDA) for global access are currently being undertaken. For adults, a single dose
of 400 mg tribendimidine was elucidated in dose-response studies (8), while the
pediatric dose of 200 mg tribendimidine was arbitrarily chosen. Population pharmaco-
kinetics indicated younger people to be less exposed to dADT due to higher drug
clearance (12). These ﬁndings question the effectiveness of the 200-mg pediatric dose,
and hence further investigations are necessary before recommending tribendimidine
for preventive chemotherapy in children (12).
The aim of the present study was to determine for the ﬁrst time the pharmacokinetic
(PK) properties of tribendimidine in African school-aged children, the main target group
of preventive chemotherapy. A tight sampling scheme was applied, in the framework
of a dose-ranging study (100 to 400 mg tribendimidine), using dried-blood-spot
technology. dADT and adADT were quantiﬁed using liquid chromatography tandem
mass spectrometry. The PK parameters were calculated by noncompartmental model-
ing. Logistic regression was used to obtain an insight into PK/pharmacodynamic (PD)
behavior.
RESULTS
Accuracy, precision, recovery, and matrix effect. After slight modiﬁcations made
to the dADT and adADT sample preparation, the accuracy and precision of analyte
extraction were evaluated and summarized in Table S1 in the supplemental material.
The extraction method quantiﬁed dADT across the dynamic range within the limits of
the FDA guidance. Concentrations were within 94% to 97% of the nominal concentra-
tions within one measurement of standards, showing most variation at the lower limit
of quantiﬁcation (LLOQ) with a relative standard deviation (SD) of 14.4%. The accuracy
of two measurements combined was between 98% and 99%, with the highest variation
at the LLOQ with 13.6%. Similarly, adADT was within the acceptance range with
measured concentrations between 94% and 105% of the nominal values with the LLOQ
again showing the highest relative standard deviation of 12.4%. The interassay accuracy
was between 95% and 101%, with the highest variation of 14.5% at the LLOQ.
As summarized in Table S2 in the supplemental material, recovery experiments
showed dADT to be recovered to approximately 91% from dried blood spots of spiked
whole-blood standards, with a slight tendency for higher recovery at low concentra-
tions (97%) than at higher concentrations (84%). However, the overall relative standard
deviation was 9.7%, which indicated an acceptable range of deviation. The matrix effect
of dADT was 82% with a variation of 8.7%, showing no dependence on analyte
concentration. The recovery of adADT was 105%  11.2%, and similarly to dADT,
showing a slight tendency for higher recovery at lower concentrations (109%) than at
higher concentrations (102%) with a maximum variation of 16.6% at low concentra-
tions. The matrix effect of adADT was independent of concentration with a mean value
of 69% and a variation of 9.9%.
Number and characteristics of study participants. A total of 102 eligible partic-
ipants participated in the PK study. We analyzed the dried blood spots of 101 children,
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of which all 11 time points were collected (n  98) or missing one time point (n  3),
excluding the samples of one child, of which we had an incomplete set of only four
time points. The PK analysis was performed on 34 children which had received 100 mg
tribendimidine, 33 which had received 200 mg, and 34 children which had obtained
400 mg. Each treatment group involved a similar distribution of sexes and were of
similar age, height, and weight (Table 1).
Pharmacokinetic proﬁles. In 99% of all samples taken between the ﬁrst (1 h) and
the last (22 h) posttreatment, both analytes could be quantiﬁed at concentrations
above the respective LLOQs. Six percent of the samples between the ﬁrst and the last
sample collected after treatment were diluted and remeasured due to dADT concen-
trations exceeding the ULOQ.
The PK concentration-over-time proﬁles of mean dADT and adADT values after oral
administration of ascending tribendimidine doses are depicted in Fig. 1 and Fig. 2,
respectively. The mean maximal concentrations (Cmax) of dADT were 666 ng/ml after
administration of 100 mg tribendimidine measured 1 h after treatment (Tmax), 850
ng/ml 3 h after administration of 200 mg tribendimidine, and 1,689 ng/ml 2 h after
administration of 400 mg tribendimidine. As for adADT, Cmax was 108 ng/ml 2 h after
the administration of 100 mg tribendimidine, 154 ng/ml 2 h after administration of 200
mg, and 307 ng/ml 3 h after administration of 400 mg tribendimidine. Three children
showed an atypical PK proﬁle: the dADT concentrations did not exceed 105 ng/ml
during 1 h to 8 h after tribendimidine administration, but Cmax was measured 22 h after
treatment with an average of 342 ng/ml (287 to 422 ng/ml). All three children belonged
to the treatment arm, which had received 200 mg tribendimidine.
TABLE 1 Participant characteristics
Characteristic
Tribendimidine dose
100 mg 200 mg 400 mg
No. of participants 34 33 34
No. of girls 13 8 10
Mean (SD)
Age (yr) 9.0 (2.2) 9.2 (2.2) 8.8 (2.4)
Ht (cm) 129 (14) 128 (11) 123 (14)
Wt (kg) 27 (6) 25 (7) 24 (6)
Egg reduction rate (%) 57 81 92
Cure rate (%) 19 42 53
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FIG 1 Mean blood concentrations with standard deviations of dADT after a single oral dose of 100 mg
tribendimidine (black diamonds with black line, n 34), 200 mg tribendimidine (gray squares with gray line,
n  33), or 400 mg tribendimidine (white triangles with black line, n  34).
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Pharmacokinetic parameters. Pharmacokinetic parameters of dADT and adADT
were calculated for each child, and median values with ranges of the 25th and 75th
percentiles of each treatment group are presented in Table 2. Median dADT Cmax values
ascended in a less than proportional manner; the slope of the power model was 0.52
(90% conﬁdence interval [CI]: 0.30, 0.72). Values for the area under the blood
concentration-time curve for 0 to 22 h (AUC0–22) increased in a dose-proportional
manner with a slope under the power model of 0.86 (90% CI  0.68 to 1.03). Little of
the area to calculate AUC∞ was extrapolated as AUC0–22, which was approximately
equal to AUC∞. As such, dADT was cleared dose-independently at rates of 31 liters/h
(200-mg dose) to 33 liters/h (100- and 400-mg doses). dADT’s half-life remained
comparable for all the dosages with values of 3.7 and 3.8 h. The mean residence time
(MRT) of dADT increased from 4.3 h (100-mg dose) to 5.6 h (200-mg dose).
The PK parameters of adADT revealed less systemic exposure than its precursor
molecule dADT, as presented in Table 2. Median Cmax values of adADT were 111 ng/ml
after treatment with 100 mg and 124 ng/ml after treatment with 200 mg tribendimi-
dine, whereas treatment with 400 mg tribendimidine resulted in a Cmax of 297 ng/ml
adADT. The Tmax of adADT was at 2 h after administration of 100 mg tribendimidine,
whereas the Tmax for the 200-mg and the 400-mg treatment arms were at 4 h
posttreatment: the adADT values for AUC0–22 and AUC∞ were 797 and 683 h · ng/ml,
respectively, after 100 mg tribendimidine administration, 1,211 and 1,260 h · ng/ml,
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FIG 2 Mean blood concentrations with the standard deviations of adADT after a single oral dose of 100 mg
tribendimidine (black diamonds with black line, n 34), 200 mg tribendimidine (gray squares with gray line,
n  33), or 400 mg tribendimidine (white triangles with black line, n  34).
TABLE 2 Pharmacokinetic parameters of dADT and adADT after treatment with 100, 200, or 400 mg tribendimidine
Compound Parameter
Median (25th–75th percentile range)
100 mg 200 mg 400 mg
dADT Cmax (ng/ml) 853 (693–1,115) 1,530 (1,150–1,960) 2,275 (1,618–2,875)
Tmax (h) 1 (1–2) 3 (2–4) 3 (2–5)
AUC0–22 (h · ng/ml) 3,019 (2,666–4,221) 6,467 (5,231–7,457) 12,530 (10,597–14,886)
AUC∞ (h · ng/ml) 3,059 (2,753–4,422) 6,638 (5,610–7,613) 12,530 (11,311–15,558)
AUMC∞ (h2 · ng/ml) 13,249 (10,615–22,175) 35,986 (29,564–53,870) 75,341 (59,252–94,861)
t1/2 (h) 3.7 (3.5–4.2) 3.8 (3.3–4.1) 3.7 (3.2–4.3)
MRT∞ (h) 4.3 (3.8–5.1) 5.6 (4.2–6.7) 6.1 (4.7–6.6)
CL/F (liters/h) 33 (24–38) 31 (27–38) 33 (27–38)
adADT Cmax (ng/ml) 111 (46–216) 124 (71–326) 297 (124–546)
Tmax (h) 2 (1–3) 4 (2–5) 4 (3–5.5)
AUC0–22 (h · ng/ml) 683 (267–1,223) 1,211 (488–2,015) 2,791 (970–3,775)
AUC∞ (h · ng/ml) 695 (290–1,293) 1,260 (545–2,238) 3,023 (986–4,583)
AUMC∞ (h2 · ng/ml) 3,914 (1,612–7,045) 8,772 (4,024–15,274) 21,472 (7,029–33,091)
t1/2 (h) 3.8 (3.2–5.0) 3.7 (3.6–4.6) 3.8 (3.5–5.0)
MRT∞ (h) 5.4 (4.8–6.3) 6.7 (5.7–7.8) 7.3 (5.8–8.0)
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respectively, after 200 mg, and 2,791 and 3,023 h · ng/ml, respectively, after 400 mg.
Area under the ﬁrst moment curve from 0 h to inﬁnity (AUMC∞) values increased from
3,914 h2 · ng/ml (100-mg dose) to 8,772 h2 · ng/ml (200-mg dose) and to 21,472 h2 ·
ng/ml (400-mg dose). adADT’s half-life remained comparable for all the dosages with
values of 3.7 and 3.8 h. The MRT was prolonged in a linear manner (R2  0.819) from
5.4 h (100-mg dose) to 6.7 h (200-mg dose) and to 7.3 h (400-mg dose).
Pharmacokinetic-pharmacodynamic relationship. There was no evidence of an
effect of Cmax or AUC on egg reduction rate or cure status using logistic regression for
analysis.
dADT acylation to adADT. There was no indication for metabolism of dADT to
adADT to be inﬂuenced by dose based on Cmax and AUC0–22 values (see Table S3 in the
supplemental material). The dADT Cmax was observed at 1.4- to 35.4-fold higher
concentrations than those of adADT, with a median ratio of 7.2, without a signiﬁcant
dose-dependent trend. As for AUC0–22 values, the dADT ratios ranged from 1.5 to 33.1,
with a median ratio of 4.6 and no statistical difference between the dosage groups.
Adverse events-PK relationship. Of the 101 children participating in this PK study,
28 children stated ill-being after treatment with one of the three tribendimidine
treatment arms: 10 children had received 100 mg tribendimidine, 8 children had
received 200 mg tribendimidine, and 10 children had received 400 mg tribendimidine.
We could not identify a relationship between adverse events and dADT and adADT
exposure, since the children with adverse events displayed the same distribution of
drug exposure found in the overall study population.
DISCUSSION
Tribendimidine is a frontrunner in the anthelminthic drug discovery and develop-
ment pipeline. Alternative anthelminthics are essential to alleviate drug pressure on
albendazole. We contributed the efforts to make tribendimidine globally accessible for
the treatment of helminth infections and conducted for the ﬁrst time a PK study in
hookworm-infected children treated with tribendimidine. The PK study was embedded
in a dose-ﬁnding study (J. Coulibaly et al., unpublished data) aiming to support the
decision on the accurate dose to treat this population and to further elucidate the
PK-pharmacodynamic relationship of tribendimidine treatment against hookworm in-
fection. For the PK sample collection, we used the dried-blood-spot technique and
analytical quantiﬁcation method of dADT (active compound) and adADT (inactive
metabolite of dADT) as described earlier by Duthaler et al. (13, 14). The few adaptions
made to the protocol did not compromise the quality of the measurements. Our data
show a less-than-proportional to proportional increase of systemic dADT exposure
when administering doses of 100, 200, or 400 mg tribendimidine. The nonaccumulative
behavior of dADT across all three doses assessed was evident by unchanged clearance
rates and dose-independent turnover rates of dADT to adADT. Similarly, Duthaler et al.
described subproportional to proportional dADT exposure following a single 25- to
400-mg tribendimidine doses in Lao adults infected with Opisthorchis viverrini. The dose
of 600 mg, however, did not lead to notably higher exposure than the 400-mg dose
(13). The PK dose ranging studies of tribendimidine conducted so far imply that the
enzymes responsible for dADT degradation are not saturated at a dose of up to 400 mg
tribendimidine.
The varying PK proﬁles of tribendimidine among patients call for caution. We
observed large interindividual differences for Tmax (1 to 22 h postadministration) and
variable Cmax. In particular, three proﬁles were atypical in that the Cmax was reached as
late as 22 h posttreatment. We do not know whether this is due to biological
differences of these participants, for instance due to polymorphism of the acetyltrans-
ferase responsible for dADT acetylation (9, 15) or ﬂoating of the tablets in the stomach
due to the enteric coating (13). We took a food effect into account by regulating the
food intake at the day of treatment to minimize variation in stomach emptying,
compound liberation, and absorption, and yet obviously ﬂoating properties could not
be controlled. There is therefore a need to develop an optimal formulation of
Pharmacokinetics of Tribendimidine in African Children Antimicrobial Agents and Chemotherapy
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tribendimidine for the treatment of soil-transmitted helminthiasis and opisthorchiasis
and to investigate in PK studies whether an enteric coating is required. We observed
few children chewing the tablets, hence destroying the enteric coating. When analyzing
their PK proﬁles we observed a tendency for a higher and earlier Cmax and no difference
in efﬁcacy and tolerability. However, further studies are required to conﬁrm this ﬁnding.
When comparing the drug exposure of this study population to the earlier study
with Lao adults diagnosed with an O. viverrini infection (13), we observed higher
exposure after treatment with 200 or 400 mg tribendimidine, but slightly quicker
elimination. In more detail, in Ivorian children we saw on average higher Cmax (200%)
and AUC (120%) values; however, the AUMC values were lower (70%). Also, Tmax and
t1/2 were shorter (around 50%). The clearance was the same (400-mg dose) or elevated
(140%; 200-mg dose) (13).
Comparing systemic dADT exposure of our study population to those of healthy
adult Chinese volunteers, which had been given the recommended dose of 400 mg, we
observed lower Cmax levels in Ivorian children (36%), but higher AUCs (290%). The Tmax
and t1/2 were again shorter in our study cohort (around 75%) than in healthy adult
Chinese subjects (9). These data demonstrate that Ivorian children show higher dADT
exposure than other populations studied so far. This is an unexpected result, since
population PK analysis of the data set of the Lao population predicted less systemic
drug exposure in children due to higher drug clearance the younger the treated
patients (12). However, these variations cannot be fully attributed to differences in age
or ethnicity since differences in the provided meals might induce ﬂotation of the tablets
and thus have a strong inﬂuence on tribendimidine’s PK properties. Population PK
modeling has been launched with our data set as was done with the studies from Laos
(12).
No evidence of an effect of Cmax and AUC on efﬁcacy was observed. A higher
systemic dADT exposure did not correlate with cure of hookworm infection or decreas-
ing egg expulsion. It might be worth highlighting that in our study most hookworm
infections were of light intensity, which might lead to a slight bias due to diagnostic
limitations as cure rates might have been overestimated. Nonetheless, it is likely that
intestinal concentrations of tribendimidine are responsible for activity on intestine-
residing helminths rather than the absorbed fraction. Few data are presently available
to aid in understanding the PK/PD relationship. PK studies in rodents have not been
conducted to date. Moreover, the in vitro activity of dADT against Necator americanus
(the hookworm species at the study site; unpublished observations) has not been
elucidated. The 50% inhibitory concentration of dADT against adult Ancylostoma
ceylanicum in vitro is high (100 g/ml) (16). Hence, relevant data are not yet available
to conclude on a PK/PD relationship.
On the other hand, in Laotians infected with O. viverrini, which resides in the host’s
bile duct, dADT exposure correlated with cure (13). There is a strong need to develop
a better understanding of the relationship between PK parameters and efﬁcacy for
anthelminthics used to treat gastrointestinal nematodes (17). To our knowledge, our
study is the ﬁrst to provide knowledge on the PK and PD for the treatment of
hookworm infections in humans. Similar studies should be conducted with standard
treatments (i.e., albendazole and mebendazole) to better understand the pharmacol-
ogy of these drugs and to identify PK markers correlating with toxicity. In the present
study, the adverse events reported by the study participants could not be correlated to
high doses or elevated pharmacokinetic parameters of dADT or adADT. Nevertheless,
we should continue to carefully assess side effects after treatment with tribendimidine
and examine the drug exposure of these individuals for a more representative statistical
evaluation.
In summary, our PK study in school-aged children showed no relationship between
dADT exposure and drug efﬁcacy (cure and egg reduction rate) and toxicity. Higher
systemic dADT exposure compared to adult populations and a less than proportional
as well as a proportional exposure in dADT’s Cmax and AUC was observed. Future
studies would beneﬁt from including patients with high infection intensities to rule out
Hiroshige et al. Antimicrobial Agents and Chemotherapy
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a potential inﬂuence of disease burden on the pharmacokinetics and pharmacodynam-
ics of tribendimidine. Moreover, an optimization of the tribendimidine formulation
might be envisaged to minimize the risk of food effects.
MATERIALS AND METHODS
Ethical approval, participant selection, and treatment. This PK study was embedded in a
dose-ﬁnding study of tribendimidine for pediatric use to treat hookworm infection, which is fully
described elsewhere (Coulibaly et al., unpublished). The clinical trial including the PK study was approved
by the ethical authorities of Switzerland (Ethikkomission Nordwest- und Zentralschweiz, project ID
2017-00139) and the Republic of Côte d’Ivoire (Comité National D’Éthique de la Recherche, reference
number 053//MSHP/CNER-kp). Eligible children to participate in the PK study had provided assent and
informed consent of their legal guardian, were hookworm positive, were aged between 6 and 12 years,
and no clinical concerns regarding study participation were present. Eligible study participants were
randomized into three treatment arms of equal size and with an equal distribution of infection
intensities. The active treatment arms were single dosages of 100, 200, or 400 mg tribendimidine.
Tribendimidine tablets of 50 mg were used for the 100-mg dose. Tablets (200 mg) were used for the 200-
and 400-mg doses. All tribendimidine tablets were obtained from Shandong Xinghua Pharmaceutical
Corporation, China, and had an enteric coating. The participants were asked to eat no breakfast at the
day of treatment. After swallowing the tablets, the children received a small snack (biscuits) and lunch
(rice, ﬁsh, and vegetable oil) approximately 4 h after treatment.
Collection of capillary blood using died blood spots. Fingers of participants were sanitized and
pricked using single-use lancets (e.g., Accu-chek Safe-T-Pro Plus; Roche Diagnostics, Rotkreuz, Switzer-
land). Blood was collected with heparinized glass capillaries (75 l; Carl Roth GmbH, Arlesheim,
Switzerland), dropped onto ﬁlter paper cards (Whatman 903 Protein Saver Snap Apart Card; GE
Healthcare, United Kingdom), and air dried for at least 5 h before storing in plastic bags containing
desiccant, as described by Duthaler et al. (13). Samples were taken before treatment (T0), and 1, 2, 3, 4,
5. 5.5, 6, 7, 8, and 22 h after treatment. The samples were stored at ambient temperature (26°C) in Côte
d’Ivoire for 4 days and then at20°C after transport to Switzerland, which have been proven to be stable
storage conditions (12, 14), until sample preparation for analysis by liquid chromatography-tandem mass
spectrometry (LC-MS/MS).
LC-MS/MS equipment and conditions. For high-performance liquid chromatography, a system
(Shimadzu, Kyoto, Japan) was used consisting of two LC-AD pumps, an online DG-3310 degasser (Sanwa
Thusho, Tokyo, Japan), a CTC HTS PAL autosampler for cooling to 10°C (CTC Analytics, Zwingen,
Switzerland), a diverter-valve (Vici Valco Instruments, Schenkon, Switzerland), and a loop for a 10-l
injection volume. Chromatographic separation was performed with a Kinetex core shell pentaﬂuorophe-
nyl column (50 by 4.6 mm; 2.6 m, 100 Å; Phenomenex, Basel, Switzerland) at 38°C at a ﬂow rate of 0.75
to 1 ml/min. The separation was achieved as described by Duthaler et al. (14), using gradients of an
aqueous phase (phase A; 10 mM ammonium acetate and 0.15% formic acid in Milli-Q water) and an
organic phase (phase B; 10 mM ammonium acetate and 0.15% formic acid in acetonitrile). All eluents and
additives were purchased from Merck Millipore (Schaffhausen, Switzerland) and were of LC-MS-grade.
The following elution proﬁle was applied: 90% B between 0 and 2.5 min, linear decrease to 5% B within
0.5 min and continued isocratic elution for 1 min, and linear increase to 90% B within 0.5 min and
continued isocratic elution for 1.5 min.
For mass spectrometry, an API 3200 instrument (AB Sciex, Framingham, MA) was used. The com-
pounds were ionized in positive mode and detected by multiple-reaction monitoring at m/z of 178.1/
133.2 for dADT, m/z of 220.2/175.0 for adADT, m/z of 184.2/for deuterated dADT (dADT-d6), and m/z of
226.2/175.00 for deuterated adADT (adADT-d6).
Preparation of standards. Standards of dADT and adADT were prepared similar to the protocol
described by Duthaler et al. (13, 14). dADT and adADT were donated by Shandong Xinhua Pharmaceu-
tical Company (Zibo, People’s Republic of China). dADT-d6 and adADT-d6 were purchased from Toronto
Research Chemicals (Ontario, Canada). Stock solutions of 1 mg/ml adADT and dADT dissolved in
methanol were diluted in acetonitrile and Milli-Q H2O (50:50) to serial dilutions, which were further
diluted 30-fold in fresh blood from six different donors (donated by the blood bank of Canton
Basel-Stadt, Switzerland), which had been adjusted to six different hematocrits (30, 35, 40, 45, 50, and
55%). The reason for not using the blood of only one donor or pooled blood is the concern of the
dried-blood-spot technique to be patient and hematocrit dependent (18). The ﬁnal concentrations of the
calibration curves were 2,000, 1,000, 750, 500, 250, 100, 75, 50, 25, 10, and 3 ng/ml for dADT and 2,000,
1,000, 500, 250, 100, 50, 25, 10, 5, 2.5, and 1 ng/ml for adADT, using blood with a hematocrit of 40%. The
concentrations of the quality controls included high, middle, and low concentrations within the dynamic
range, as well as an LLOQ sample. The concentrations of the quality controls were 1,500, 150, 9, and 3
ng/ml for dADT and 1,500, 150, 3, and 1 ng/ml for adADT. All quality control samples were prepared in
the six blood samples from the six donors that had been adjusted to the six different hematocrit values.
Blank blood was used for double-blank samples (extraction of analyte-free blood without addition of
internal standards) and blank samples (extraction of analyte-free blood following the normal procedure).
Sample extraction. The extraction method was adapted from Duthaler et al. (13, 14). Two disks 3
mm in diameter were punched out of the DBS ﬁlter paper and placed in a 1.5-ml Eppendorf tube. The
internal standards dADT-d6 and adADT-d6 were prepared from 500-g/ml stock solutions in methanol.
The aqueous extraction solvent (50 l of H2O containing 0.2% formic acid and 10 ng/ml internal
standard) was added to the dried blood spots, the samples were vortex mixed to reliably moisten them
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and left at room temperature for 30 min. Then, the tubes were agitated for 20 min at 1,400 rpm and 21°C
(Thermomixer R; Eppendorf, Hamburg, Germany). Organic extraction solvent (150 l of acetonitrile) was
added, vortex mixed, and ultrasonicated for 10 min. Double-blank samples were processed in the same
manner, except for using extraction solvents not containing internal standards. The samples were
centrifuged at 14,000 rpm (5415R centrifuge; Eppendorf) for 10 min at 21°C, and the supernatant was
placed in a 96-deep well plate (deep well, 500 l; Eppendorf), which was sealed with a sealing mat
(Eppendorf) and kept at room temperature until analyzed.
Quantiﬁcation. Analyst 1.6.2 software (AB Sciex) was used for peak integration and calculation of the
calibration curves from at least eight calibrators using weighted linear regression (y  1/x2). Samples
exceeding the upper limit of quantiﬁcation were diluted with double-blank samples.
Method validation. The extraction method for both analytes, dADT and adADT, underwent a partial
validation, since the extraction method was slightly adapted from the fully validated method (14). For
this study, we tested the intra- and interassay accuracy and precision, as well as the recovery and matrix
effect. To determine the intra- and interassay accuracy and precision, we processed two sets of standards
as described above. The accuracy was calculated as the percentage of the measured concentration
compared to the nominal concentration. The precision was calculated as the percentage of the standard
deviation of multiples compared to their average value. For intra-assay accuracy and precision, the
averages of six replicates were used; for interassay accuracy and precision, the average of 12 replicates
was used. We followed the US FDA-guidance for industry for bioanalytical method validation (19). The
guidance recommends limits for quantiﬁcation of analytes of the high, middle, and low concentrations
to be within 15% of their nominal concentration or 20% for the LLOQ. The recovery was tested by
comparing the area under the curves of the analytes after their extraction from blood (normal procedure)
to the area under the curves of the analytes when added after extraction of blank blood. The matrix effect
was tested by comparing the area under the curves of the analytes when added after extraction of blank
blood to the area under the curves of the analytes, which were added to extraction solvent.
Pharmacokinetic and statistical analyses. The PK parameters of dADT and adADT were determined
for each patient, with a noncompartmental analysis using the software WonNonlin (version 5.2; Certara,
Princeton, NJ). Maximal concentration (Cmax [nanograms per milliliter]) values and the time at Cmax (Tmax
[hours posttreatment]) were observed values. The area under the blood concentration-time curves (AUC
[hours multiplied by nanograms per milliliter]) and the area under the ﬁrst moment curve (AUMC [hours
squared multiplied by nanograms per milliliter]) were calculated using the linear trapezoidal rule. We
calculate the AUC values of the all observed analyte concentrations between sampling time point 0 h and
time point 22 h after treatment (AUC0–22), as well as the AUC and AUMC values of the extrapolated total
drug exposure from time point 0 h to inﬁnity (AUC∞ and AUMC∞) for curves with at least three
observations in the elimination phase. Also the analytes’ half-life (t1/2 [hours posttreatment]) was
calculated if at least three observations were available in the elimination phase. The mean residence time
(MRT [hours]) was calculated as the ratio of AUMC∞ to AUC∞. Drug clearance (CL/F [liters per hour]) was
determined by dividing the dose by the AUC0–22. Dose proportionality was assessed using the power
model using a conﬁdence interval of 90% (SAS for Windows, version 9.4). For each treatment arm, the
50th percentile was calculated as the representative value plus the 25th and 75th percentiles as
indicators of the range of values using Microsoft Excel.
The egg reduction rate was calculated as the decreased percentage of geometric mean egg counts
found at follow-up compared to the geometric mean egg count found at baseline using the quadruple
Kato-Katz method. The cure rate was deﬁned as the percentage of patients that were hookworm
negative at follow-up. To evaluate relationship between pharmacokinetics and pharmacodynamics, the
cure status was analyzed using univariate logistic regression using Cmax and AUC as predictors (SAS for
Windows, version 9.4). The egg reduction rate was modeled using univariate beta regression using the
same predictors as for cure status. Statistical signiﬁcance was declared if the P value for the predictor was
0.05.
Dose dependence of metabolic turnover of dADT to adADT was assessed by comparing dADT to
adADT ratios among treatment groups and determining their differences using the Mann-Whitney U test
(StatsDirect software, version 2.7.7).
We furthermore evaluated the systemic drug exposure as a cause for adverse events. In brief, all study
participants were asked about their well-being prior to treatment, 3 h after treatment, and 24 h after
treatment to monitor acute drug-related effects. The participants were asked about the presence (on a
scale) or absence of headache, stomach ache, itching, thrill, nausea, vomiting, and diarrhea, as well as
sensation of fever and allergic reactions. To evaluate the effect of dADT and adADT’s pharmacokinetic
parameters (Cmax, AUC, AUMC, and MRT) as a cause for ill-being, we compared their magnitude (25th,
50th, and 75th percentiles) for the individuals who had stated the presence of ill-being at any time after
treatment to the overall values of their respective treatment group.
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